-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Now, Assistant Professor Salk and internal medicine scientist Edward Stites uses computer modeling and cell research to find that more patients can be helped by a common targeted therapy, which is more than previously thought
"Patients with colorectal cancer have tried all standard treatment options, but still see their cancer progress, they need new options
Stites is interested in detecting drugs that target the EGFR (epidermal growth factor receptor) protein
In 2004, the U.
Early research in the Stites laboratory showed that not all RAS mutations work in the same way and can explain a well-known but little-known exception
The cancer cells used by the researchers were identical except for the specific RAS mutation
The researchers also examined how different RAS mutants bind to another protein called NF1
In the end, the researchers discovered 10 different RAS mutations, which did not hinder the use of EGFR inhibitors
Steith is the development chairman of the Hearst Foundation, and he emphasized that this research will also help validate the mathematics and calculation methods developed by his team
The first author of the paper is Thomas McFall, who was a postdoctoral researcher at Salk University and now works at the Medical College of Wisconsin
The research was funded by the National Institutes of Health K22CA216318, DP2AT011327, T32CA009370 and P30CA014195, and the US Department of Defense W81XWH-20-1-0538
Journal Reference :
Thomas McFall, Edward C.
